Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study

Giorgio Tonini, Tamara Pahor, Franco Colonna, Umberto De Vonderweid

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 ± 3 wks, birth weight 824 ± 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 ± 3 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d iv) and subcutaneous rhGH at different doses: 0.1 (n=1), 0.2 (n=2) or 0.3 (n=2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were signicantly higher (p <0.001), rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.

Original languageEnglish
Pages (from-to)291-294
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Volume10
Issue number3
Publication statusPublished - 1997

Fingerprint

Extremely Low Birth Weight Infant
Bronchopulmonary Dysplasia
Human Growth Hormone
Premature Infants
Dexamethasone
Growth Hormone
C-Peptide
Urea
Nitrogen
Artificial Respiration
Birth Weight
Gestational Age
Steroids
Body Weight
Lung
Growth

Keywords

  • Bronchopulmonary dysplasia
  • C-peptide
  • Dexamethasone
  • Growth hormone
  • Preterm newborn

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study. / Tonini, Giorgio; Pahor, Tamara; Colonna, Franco; De Vonderweid, Umberto.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 10, No. 3, 1997, p. 291-294.

Research output: Contribution to journalArticle

@article{88df34afc8764d7e8124d9bfaf7c00f2,
title = "Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study",
abstract = "Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 ± 3 wks, birth weight 824 ± 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 ± 3 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d iv) and subcutaneous rhGH at different doses: 0.1 (n=1), 0.2 (n=2) or 0.3 (n=2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were signicantly higher (p <0.001), rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.",
keywords = "Bronchopulmonary dysplasia, C-peptide, Dexamethasone, Growth hormone, Preterm newborn",
author = "Giorgio Tonini and Tamara Pahor and Franco Colonna and {De Vonderweid}, Umberto",
year = "1997",
language = "English",
volume = "10",
pages = "291--294",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "3",

}

TY - JOUR

T1 - Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study

AU - Tonini, Giorgio

AU - Pahor, Tamara

AU - Colonna, Franco

AU - De Vonderweid, Umberto

PY - 1997

Y1 - 1997

N2 - Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 ± 3 wks, birth weight 824 ± 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 ± 3 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d iv) and subcutaneous rhGH at different doses: 0.1 (n=1), 0.2 (n=2) or 0.3 (n=2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were signicantly higher (p <0.001), rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.

AB - Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 ± 3 wks, birth weight 824 ± 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 ± 3 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d iv) and subcutaneous rhGH at different doses: 0.1 (n=1), 0.2 (n=2) or 0.3 (n=2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were signicantly higher (p <0.001), rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.

KW - Bronchopulmonary dysplasia

KW - C-peptide

KW - Dexamethasone

KW - Growth hormone

KW - Preterm newborn

UR - http://www.scopus.com/inward/record.url?scp=0031008362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031008362&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 291

EP - 294

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 3

ER -